An exclusive interview with Hal Andrews, President and CEO of Trilliant Health, on the topic of price transparency and how regulators and companies can contain costs for patients. An exclusive interview with Hal Andrews, President and CEO of Trilliant Health, on the topic of price transparency and how regulators and companies can contain costs for patients. | | |
|
Sixty-one-year-old Lilit Gagikovna Baltaian, MD, is on the run after being convicted of fraudulently billing Medicare alongside co-conspirators at home health agencies. A federal court in California sentenced her to 54 months in prison. Sixty-one-year-old Lilit Gagikovna Baltaian, MD, is on the run after being convicted of fraudulently billing Medicare alongside co-conspirators at home health agencies. A federal court in California sentenced her to 54 months in prison. | | |
|
Faranak Firozan, 47, is a cybersecurity expert at Nvidia who regularly spoke on the topic of “cyber laundering.” Prosecutors in California allege she submitted fraudulent medical claims to an employer-sponsored insurance plan, bilking Cigna out of $100,000. Faranak Firozan, 47, is a cybersecurity expert at Nvidia who regularly spoke on the topic of “cyber laundering.” Prosecutors in California allege she submitted fraudulent medical claims to an employer-sponsored insurance plan, bilking Cigna out of $100,000. | | |
|
|
One of the picks for the Advisory Committee on Immunization Practices, Robert Malone, MD, is known for his outspoken criticism of mRNA vaccines, particularly for COVID-19. Malone believes the technology is unsafe and has been accused by public health officials of spreading medical misinformation. One of the picks for the Advisory Committee on Immunization Practices, Robert Malone, MD, is known for his outspoken criticism of mRNA vaccines, particularly for COVID-19. Malone believes the technology is unsafe and has been accused by public health officials of spreading medical misinformation. | | |
|
The insurer alleges The Guardian misrepresented the facts in a May 21 exposé that accused the insurer of pressuring nursing homes to delay and deny hospital transfers. The insurer alleges The Guardian misrepresented the facts in a May 21 exposé that accused the insurer of pressuring nursing homes to delay and deny hospital transfers. | | |
|
The exact number of rehires is unclear. However, the move marks the largest number of workers returning to the Centers for Disease Control and Prevention since the agency was targeted for firings by Elon Musk's DOGE. The exact number of rehires is unclear. However, the move marks the largest number of workers returning to the Centers for Disease Control and Prevention since the agency was targeted for firings by Elon Musk's DOGE. | | |
|
|
The Centers for Medicare & Medicaid Services is updating the ACO REACH program—which supports providers caring for rural and low-income populations—to promote patient health as a strategy to reduce costs. The Centers for Medicare & Medicaid Services is updating the ACO REACH program—which supports providers caring for rural and low-income populations—to promote patient health as a strategy to reduce costs. | | |
|
The Centers for Medicare & Medicaid Services said it will increase medical coding staff from 40 to 2,000 and begin addressing its backlog of audits on Medicare Advantage plans in an effort to spot signs of fraud and abuse. The Centers for Medicare & Medicaid Services said it will increase medical coding staff from 40 to 2,000 and begin addressing its backlog of audits on Medicare Advantage plans in an effort to spot signs of fraud and abuse. | | |
|
|
The American Medical Association passed a resolution at its recent annual meeting seeking to “maximize trust” around how these models reach conclusions.
The American Medical Association passed a resolution at its recent annual meeting seeking to “maximize trust” around how these models reach conclusions. | | |
|
The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public. The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public. | | |
|
